HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables): amplitud de titulares 0.0% · flujo de acciones +5.1% · nuevas posiciones netas 0.0% · fórmula
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 131 | -1 | 91.15M | $6.60B | +6 | −8 |
| Q1 2026 | 136 | +1 | 88.77M | $5.36B | +7 | −7 |
| Q4 2025 | 135 | -1 | 97.38M | $6.16B | +1 | −1 |
| Q3 2025 | 22 | +1 | 49.86M | $3.66B | +1 | −1 |
| Q2 2025 | 19 | 0 | 43.24M | $2.25B | n/a | n/a |
| Q1 2025 | 16 | -1 | 15.61M | $996.39M | n/a | −1 |
| Q4 2024 | 17 | +3 | 17.59M | $840.95M | +4 | −1 |
| Q3 2024 | 13 | -1 | 6.97M | $398.81M | n/a | −1 |
| Q2 2024 | 14 | n/a | 8.14M | $426.06M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (pasivo) | 13.20M | n/a | $686.67M | 0.0% | n/c | 1 | SEC ↗ ×21 |
| 2 | The Vanguard Group ✦ (pasivo) | 12.25M | n/a | $637.02M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (pasivo) | 5.94M | -1.9% | $308.74M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | Arrowstreet Capital ✦ | 2.54M | +127.8% | $132.19M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 5 | Geode Capital Management ✦ (pasivo) | 2.43M | -23.2% | $126.56M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | T. Rowe Price ✦ | 1.03M | -13.0% | $53.70M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 1.02M | +64.4% | $53.00M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Norges Bank ✦ (pasivo) | 865.57K | +3.8% | $45.03M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Capital World Investors ✦ | 782.00K | +4.5% | $40.68M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Millennium Management ✦ | 690.47K | +1534.9% | $35.92M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 11 | Two Sigma Investments ✦ | 439.84K | -31.9% | $22.88M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 12 | Marshall Wace ✦ | 389.13K | -16.1% | $20.24M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 381.75K | -8.6% | $19.86M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 378.80K | +1043.1% | $19.71M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 15 | Renaissance Technologies ✦ | 338.61K | +182.2% | $17.61M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 311.40K | +292.1% | $16.20M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 17 | Wellington Management ✦ | 103.67K | +94.5% | $5.39M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 18 | Fidelity (FMR) ✦ | 84.56K | n/a | $4.40M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 19 | Gotham Asset Management ✦ | 68.05K | +109.2% | $3.54M | 0.0% | ▲ Add | 5 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 8 tenedores, 32.79M acciones, $43.93M declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer, Director · 200 acc. · $22,102
Officer, Director · 11.90K acc. · $1.31M
Officer, Director · 3.09K acc. · $336,526
Officer, Director · 4.81K acc. · $520,341
Officer, Director · 8.60K acc. · $954,867
Officer, Director · 200 acc. · $22,739
Officer, Director · 900 acc. · $101,502
Officer, Director · 10.30K acc. · $1.15M
Officer, Director · 1.78K acc. · $197,245
Officer, Director · 9.92K acc. · $1.09M
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología